Kidney transplant patients may think clearer with once-daily pill switch
NCT ID NCT04838288
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 56 stable kidney transplant patients to see if switching their anti-rejection medication from twice-daily tacrolimus to once-daily Envarsus XR improved their thinking skills and quality of life. Participants took tests of memory, attention, and reasoning before and after the switch. The goal was to find out if the new drug could reduce brain fog and make daily life better.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL TRANSPLANT are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
VUMC
Nashville, Tennessee, 37232, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could the type of anesthesia affect kidney transplant success?
- New drug aims to fight skin cancer in transplant patients
- New ultrasound technique could predict kidney transplant success without needles
- Kidney transplant study compares immune effects of two common drugs
- Scientists probe immune cells to predict transplant rejection
- New drug aims to stop kidney disease from coming back after transplant